| Market Cap | 207.19M | P/E | - | EPS this Y | 95.60% | Ern Qtrly Grth | - |
| Income | -7M | Forward P/E | -4.47 | EPS next Y | 425.00% | 50D Avg Chg | -38.00% |
| Sales | 82.57M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -51.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 2.30 | Quick Ratio | 0.95 | Shares Outstanding | 45.98M | 52W Low Chg | 21.00% |
| Insider Own | 1.22% | ROA | 5.15% | Shares Float | 34.24M | Beta | 1.74 |
| Inst Own | 51.21% | ROE | - | Shares Shorted/Prior | 10.53K/7.56K | Price | 2.10 |
| Gross Margin | 75.94% | Profit Margin | -8.47% | Avg. Volume | 32,773 | Target Price | 10.50 |
| Oper. Margin | 14.93% | Earnings Date | Oct 10 | Volume | 60,733 | Change | -12.13% |
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
